The Genother biocluster, dedicated to accelerating the development of gene therapy drugs, of which Genethon is one of the founders, is one of the 5 winners of the France 2030 call for expressions of interest. This labelling, announced on 16 May by the French President, will strengthen France’s leadership in the field of gene therapy, one of the most dynamic areas of biomedical research.
During his visit to the Institut Curie on 16 May, Emmanuel Macron announced the labelling of 12 new university hospital institutes and 4 new bioclusters, including Genother. This marks a major step in the creation of a unique ecosystem in Europe to meet the scientific, technological, and economic challenges of gene therapy.
“The labelling of Genother, driven by our laboratory Genethon, finally responds to the desire, fiercely supported by our association for nearly a decade, to have the means to develop and market these innovative medicines in France. This biocluster allows France to have the basis of a sector of excellence from fundamental research to the provision of treatments. This is a major asset for securing our country’s health independence and creating thousands of skilled jobs in this sector at a time when we know that 20% of new medicines by 2025 will be derived from gene therapy,” said Laurence Tiennot-Herment, President of AFM-Téléthon.